{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:43:13Z","timestamp":1777956193562,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Many patients with mucinous appendiceal adenocarcinoma experience peritoneal recurrence despite complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Prior work has demonstrated that repeat CRS\/HIPEC can prolong survival in select patients. We sought to validate these findings using outcomes from a high-volume center.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>Patients with mucinous appendiceal adenocarcinoma who underwent CRS\/HIPEC at MD Anderson Cancer Center between 2004 and 2021 were stratified by whether they underwent CRS\/HIPEC for recurrent disease or as part of initial treatment. Only patients who underwent complete CRS\/HIPEC were included. Initial and recurrent groups were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 437 CRS\/HIPECs performed for mucinous appendiceal adenocarcinoma, 50 (11.4%) were for recurrent disease. Patients who underwent CRS\/HIPEC for recurrent disease were more often treated with an oxaliplatin or cisplatin perfusion (35%\/44% recurrent vs. 4%\/1% initial, <jats:italic>p<\/jats:italic> &lt; 0.001), had a longer operative time (median 629 min recurrent vs. 511 min initial, <jats:italic>p<\/jats:italic> = 0.002), and had a lower median length of stay (10 days repeat vs. 13 days initial, <jats:italic>p<\/jats:italic> &lt; 0.001). Thirty-day complication and 90-day mortality rates did not differ between groups. Both cohorts enjoyed comparable recurrence free survival (<jats:italic>p<\/jats:italic> = 0.82). Compared with patients with recurrence treated with systemic chemotherapy alone, this select cohort of patients undergoing repeat CRS\/HIPEC enjoyed better overall survival (<jats:italic>p<\/jats:italic> &lt; 0.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In appropriately selected patients with recurrent appendiceal mucinous adenocarcinoma, CRS\/HIPEC can provide survival benefit equivalent to primary CRS\/HIPEC and that may be superior to that conferred by systemic therapy alone in select patients. These patients should receive care at a high-volume center in the context of a multidisciplinary team.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-023-14422-2","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T22:01:19Z","timestamp":1698098479000},"page":"614-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit"],"prefix":"10.1245","volume":"31","author":[{"given":"Neal","family":"Bhutiani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis E.","family":"Grotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth J.","family":"Concors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Helmink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanwal P.","family":"Raghav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa W.","family":"Taggart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A.","family":"Beaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Royal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelio","family":"Matamoros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Scally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safia","family":"Rafeeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul F.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith F.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"issue":"20","key":"14422_CR1","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449\u201356.","journal-title":"J Clin Oncol."},{"issue":"1","key":"14422_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/01.sla.0000231705.40081.1a","volume":"245","author":"RM Smeenk","year":"2007","unstructured":"Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104\u20139.","journal-title":"Ann Surg."},{"issue":"9","key":"14422_CR3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/bjs.6235","volume":"95","author":"D Elias","year":"2008","unstructured":"Elias D, Honor\u00e9 C, Ciuchend\u00e9a R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008;95(9):1164\u201371.","journal-title":"Br J Surg."},{"issue":"3","key":"14422_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ejso.2014.08.476","volume":"41","author":"AC Lord","year":"2015","unstructured":"Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol. 2015;41(3):396\u20139.","journal-title":"Eur J Surg Oncol."},{"issue":"6","key":"14422_CR5","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1007\/s00268-015-2986-8","volume":"39","author":"JF Wong","year":"2015","unstructured":"Wong JF, Tan GH, Wang W, Soo KC, Teo MC. Repeat cytoreductive surgery and hipec for peritoneal surface malignancy and peritoneal carcinomatosis. World J Surg. 2015;39(6):1578\u201383.","journal-title":"World J Surg."},{"issue":"1","key":"14422_CR6","first-page":"129","volume":"7","author":"H Mogal","year":"2016","unstructured":"Mogal H, Chouliaras K, Levine EA, Shen P, Votanopoulos KI. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol. 2016;7(1):129\u201342.","journal-title":"J Gastrointest Oncol."},{"issue":"11","key":"14422_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ejso.2013.08.017","volume":"39","author":"A Sardi","year":"2013","unstructured":"Sardi A, Jimenez WA, Nieroda C, Sittig M, Macdonald R, Gushchin V. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Eur J Surg Oncol. 2013;39(11):1207\u201313.","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"14422_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jamcollsurg.2012.04.023","volume":"215","author":"KI Votanopoulos","year":"2012","unstructured":"Votanopoulos KI, Ihemelandu C, Shen P, Stewart JH, Russell GB, Levine EA. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012;215(3):412\u20137.","journal-title":"J Am Coll Surg."},{"issue":"1","key":"14422_CR9","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1503\/cjs.002519","volume":"63","author":"E Jost","year":"2020","unstructured":"Jost E, Mack LA, Sideris L, Dube P, Temple W, Bouchard-Fortier A. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study. Can J Surg. 2020;63(1):E71-e79.","journal-title":"Can J Surg."},{"issue":"6","key":"14422_CR10","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1245\/s10434-021-11233-1","volume":"29","author":"F Lopez-Ramirez","year":"2022","unstructured":"Lopez-Ramirez F, Gushchin V, Sittig M, et al. Iterative cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent mucinous adenocarcinoma of the appendix. Ann Surg Oncol. 2022;29(6):3390\u2013401.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"14422_CR11","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1245\/s10434-022-11441-3","volume":"29","author":"CD Valenzuela","year":"2022","unstructured":"Valenzuela CD, Levine EA, Mangieri CW, et al. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for cancers with peritoneal metastasis: a 30-year institutional experience. Ann Surg Oncol. 2022;29(6):3436\u201345.","journal-title":"Ann Surg Oncol."},{"key":"14422_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2021.101572","volume":"38","author":"PA Sutton","year":"2021","unstructured":"Sutton PA, O\u2019Dwyer ST, Barriuso J, et al. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy. Surg Oncol. 2021;38:101572.","journal-title":"Surg Oncol."},{"issue":"13","key":"14422_CR13","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1245\/s10434-020-08482-x","volume":"27","author":"BD Powers","year":"2020","unstructured":"Powers BD, Felder S, Veerapong J, et al. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is not associated with prohibitive complications: results of a multiinstitutional retrospective study. Ann Surg Oncol. 2020;27(13):4883\u201391.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"14422_CR14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/0959-8049(96)00178-5","volume":"32a","author":"FA Zoetmulder","year":"1996","unstructured":"Zoetmulder FA, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Cancer. 1996;32a(10):1727\u201333.","journal-title":"Eur J Cancer."},{"issue":"3","key":"14422_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/cancers15030607","volume":"15","author":"EM Pasqual","year":"2023","unstructured":"Pasqual EM, Londero AP, Robella M, et al. Repeated cytoreduction combined with hyperthermic intraperitoneal chemotherapy (hipec) in selected patients affected by peritoneal metastases: Italian PSM oncoteam evidence. Cancers (Basel). 2023;15(3):607.","journal-title":"Cancers (Basel)."},{"issue":"9","key":"14422_CR16","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1245\/s10434-016-5209-0","volume":"23","author":"TE Grotz","year":"2016","unstructured":"Grotz TE, Mansfield PF, Royal RE, et al. Intrathoracic chemoperfusion decreases recurrences in patients with full-thickness diaphragm involvement with mucinous appendiceal adenocarcinoma. Ann Surg Oncol. 2016;23(9):2914\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"14422_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1245\/s10434-019-07218-w","volume":"26","author":"HA Choudry","year":"2019","unstructured":"Choudry HA, Bednar F, Shuai Y, et al. Repeat cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion is feasible and offers survival benefit in select patients with peritoneal metastases. Ann Surg Oncol. 2019;26(5):1445\u201353.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"14422_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1245\/s10434-022-12392-5","volume":"30","author":"CW Mangieri","year":"2023","unstructured":"Mangieri CW, Valenzuela CD, Solsky IB, et al. Switching perfusion agents for repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: surgical dogma or evidence-based practice? Ann Surg Oncol. 2023;30(1):384\u201391.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"14422_CR19","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1245\/s10434-021-10929-8","volume":"29","author":"CE Guerra-Londono","year":"2022","unstructured":"Guerra-Londono CE, Owusu-Agyemang P, Corrales G, et al. Risk of intraoperative hyperthermia and outcomes in adults undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2022;29(3):2089\u201399.","journal-title":"Ann Surg Oncol."},{"issue":"22","key":"14422_CR20","first-page":"6384","volume":"60","author":"RM Phillips","year":"2000","unstructured":"Phillips RM, Burger AM, Loadman PM, Jarrett CM, Swaine DJ, Fiebig H-H. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development1. Cancer Res. 2000;60(22):6384\u201390.","journal-title":"Cancer Res."},{"issue":"1","key":"14422_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","volume":"1","author":"J Verweij","year":"1990","unstructured":"Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anti-Cancer Drugs. 1990;1(1):5\u201314.","journal-title":"Anti-Cancer Drugs"},{"issue":"8","key":"14422_CR22","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1245\/s10434-014-4335-9","volume":"22","author":"JH Choe","year":"2015","unstructured":"Choe JH, Overman MJ, Fournier KF, et al. Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann Surg Oncol. 2015;22(8):2578\u201384.","journal-title":"Ann Surg Oncol."},{"key":"14422_CR23","doi-asserted-by":"crossref","unstructured":"Shen JP, Yousef AM, Zeineddine FA, et al. A prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma. 2022:2022.2012.2006.22283164.","DOI":"10.52519\/00097"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14422-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T21:39:07Z","timestamp":1701725947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14422-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["14422"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14422-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}